The SocietyMore than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS communityBecome an ERS member
Respiratory tumours are a major part of daily practice for many respiratory physicians and lung cancer remains the biggest cancer killer in Europe, but there continues to be developments in surgical practice, treatments, and more recently, promising new targeted therapies.
The ERS International Congress programme includes a dedicated thoracic oncology track that has been developed by experts in the field. The track includes a variety of activities for health professionals who are involved in the management of respiratory tumours and for researchers with an interest in this disease area.
We spoke to ERS officers who specialise in thoracic oncology to find out what you can expect from the hybrid Congress and which programme highlights should not be missed. See what they told us:
Q: What are you most looking forward to at this year’s Congress in the thoracic oncology field?
A: After two virtual Congress years, I am most looking forward to an on-site ERS Congress and meeting many colleagues and friends in person again – within the thoracic oncology field as well as the respiratory community!
Q: Is there a specific session in this track that should not be missed?
A: There will be many attractive sessions within our thoracic oncology programme track, but if I have to pick one, it will be the interactive and worthwhile discussions in the oral presentation and poster sessions.
Q: What do you think will be the popular topics in the thoracic oncology field at this year’s Congress, and what will be a highlight for you?
A: This years ERS Congress has a really exciting thoracic oncology offering which spans diagnosis and management, and there are highlights in both pleural and thoracic malignancy. I think the most popular topics for our Assembly will be sessions on malignant effusion diagnostics and management, and sessions on screening and early diagnosis of lung cancer. A particular highlight I am looking forward to is the pro/con debate on aggressive management of the solitary pulmonary nodule – this is a situation encountered by all pulmonologists every day, and I look forward to a strident discussion!
Q: What does congress offer to early career professionals who specialise in thoracic oncology?
A: This years Congress offers the early career members the opportunity to share their research work with a panel of experts in the field of thoracic oncology and receive relevant insights from them. For the first time we will have the Networking Excellence Training programme, where early career members will have the possibility to participate in several sessions dedicated to scientific communication, namely manuscript writing and publishing, clinical and research career development and presentation skills.
The Highlights for the ERS 2022 Congress for thoracic oncology include the State of the Art, Pro/con debate about pulmonary nodules and the symposium dedicated to malignant pleural effusion: applying the evidence of 2022. These sessions present a great learning opportunity for early career professionals who specialise in thoracic oncology.
